Neuroprotective actions of peripherally administered insulin-like growth factor I in the injured olivo-cerebellar pathway

Eur J Neurosci. 1999 Jun;11(6):2019-30. doi: 10.1046/j.1460-9568.1999.00623.x.


Exogenous administration of insulin-like growth factor I (IGF-I) restores motor function in rats with neurotoxin-induced cerebellar deafferentation. We first determined that endogenous IGFs are directly involved in the recovery process because infusion of an IGF-I receptor antagonist into the lateral ventricle blocks gradual recovery of limb coordination that spontaneously occurs after partial deafferentation of the olivo-cerebellar circuitry. We then analysed mechanisms whereby exogenous IGF-I restores motor function in rats with complete damage of the olivo-cerebellar pathway. Treatment with IGF-I normalized several markers of cell function in the cerebellum, including calbindin, glutamate receptor 1 (GluR1), gamma-aminobutyric acid (GABA) and glutamate, which are all depressed after 3-acetylpyridine (3AP)-induced deafferentation. IGF-I also promoted functional reinnervation of the cerebellar cortex by inferior olive (IO) axons. In the IO, increased expression of bax in neurons and bcl-X in astrocytes after 3AP was significantly reduced by IGF-I treatment. On the contrary, IGF-I prevented the decrease in poly-sialic-acid neural cell adhesion molecule (PSA-NCAM) and GAP-43 expression induced by 3AP in IO cells. IGF-I also significantly increased the number of neurons expressing bcl-2 in brainstem areas surrounding the IO. Altogether, these results indicate that subcutaneous IGF-I therapy promotes functional recovery of the olivo-cerebellar pathway by acting at two sites within this circuitry: (i) by modulating death- and plasticity-related proteins in IO neurons; and (ii) by impinging on homeostatic mechanisms leading to normalization of cell function in the cerebellum. These results provide insight into the neuroprotective actions of IGF-I and may be of practical consequence in the design of new therapeutic approaches for neurodegenerative diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Ataxia / physiopathology
  • Cerebellum / drug effects*
  • Cerebellum / physiopathology
  • Denervation
  • Humans
  • Injections, Intraventricular
  • Insulin-Like Growth Factor Binding Proteins / metabolism
  • Insulin-Like Growth Factor I / pharmacology*
  • Male
  • Nerve Regeneration / drug effects
  • Neural Pathways / drug effects
  • Neural Pathways / physiopathology
  • Neuroprotective Agents / pharmacology*
  • Neurotoxins / pharmacology
  • Olivary Nucleus / drug effects*
  • Olivary Nucleus / physiopathology
  • Pyridines / pharmacology
  • Rats
  • Rats, Wistar
  • Recombinant Proteins
  • Somatomedins / physiology


  • Insulin-Like Growth Factor Binding Proteins
  • Neuroprotective Agents
  • Neurotoxins
  • Pyridines
  • Recombinant Proteins
  • Somatomedins
  • 3-acetylpyridine
  • Insulin-Like Growth Factor I